Nuveen Preferred and Income Term Fund (JPI) 24.40

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nuveen Preferred and Income Term Fund (JPI) 24.40 $JPI

Nuveen Closed-End Funds Declare Distributions
BusinessWire - Mon Aug 01, 3:30PM CDT
--Regular Monthly Tax-Exempt and Taxable Fund Distributions
JHA: 10.26 (-0.01), NTC: 14.28 (-0.03), JHD: 10.14 (-0.01), NKG: 14.55 (-0.01), NBD: 22.98 (+0.02), NOM: 16.72 (-0.53), JLS: 23.66 (+0.05), JQC: 8.36 (+0.02), NXC: 16.67 (-0.08), JPI: 24.40 (+0.11), NBB: 22.65 (+0.04), NKX: 17.23 (+0.08), NSL: 6.24 (+0.05), JHY: 10.32 (-0.10), JPS: 9.58 (+0.03), NAZ: 17.08 (+0.12), JPW: 16.56 (-0.08), NNC: 14.95 (+0.03), NVX: 16.82 (+0.08), JMT: 23.10 (+0.20), JMM: 7.39 (-0.02), NJV: 16.46 (-0.06), NCB: 18.45 (-0.03), NCA: 11.29 (-0.02), NRK: 14.52 (+0.05), NNY: 10.50 (+0.06), NMI: 12.59 (-0.02), NVG: 16.38 (+0.05), JSD: 15.98 (+0.02), NZF: 15.98 (+0.03), NQM: 16.50 (+0.03), NUW: 19.00 (+0.04), NQP: 15.35 (+0.01), NZH: 15.91 (+0.07), NQS: 15.61 (-0.02), JRI: 17.10 (-0.03), JFR: 10.65 (+0.02), NMY: 14.38 (+0.06), NUO: 16.78 (+0.07), NHA: 10.10 (-0.03), NMZ: 15.00 (+0.04), JRO: 10.63 (+0.11), NUV: 10.72 (+0.03), NMO: 15.07 (+0.01), NYV: 16.19 (-0.06), NMS: 17.10 (unch), NMT: 15.64 (+0.11), NUM: 15.36 (-0.03), NEV: 17.09 (-0.01), NIQ: 13.87 (+0.03), NIM: 10.97 (+0.01), NPI: 15.46 (+0.02), NPF: 15.14 (+0.05), DRA: 17.12 (+0.03), NPM: 15.38 (+0.03), JPC: 10.37 (-0.01), NTX: 15.77 (-0.02), NPP: 16.48 (+0.09), JGH: 15.05 (-0.12), NPN: 17.15 (unch), NXJ: 15.43 (+0.01), NAD: 15.74 (+0.01), NXN: 14.71 (+0.02), NEA: 15.02 (+0.03), NAC: 16.90 (-0.01), NXP: 15.48 (-0.24), NPV: 14.95 (+0.02), NXQ: 14.84 (+0.09), NXR: 15.60 (+0.04), NAN: 15.58 (+0.02), NID: 14.22 (+0.04)

Nuveen Closed-End Funds to Host Preferred Securities Conference Call
BusinessWire - Mon Apr 25, 3:30PM CDT
Nuveen Investments, a leading global provider of investment services to individual investors and their financial advisors, today announced it will host a conference call to provide advisors and investors with an update on the preferred securities market.
JPI: 24.40 (+0.11), JPC: 10.37 (-0.01)

Two Nuveen Closed-End Funds Announce Investment Policy Changes
BusinessWire - Thu Dec 17, 3:31PM CST
Nuveen Investments, today announced that the Board of Trustees of two of its closed-end funds has approved the funds' ability to more broadly invest in US dollar-denominated non-U.S. securities. The two funds are the Nuveen Preferred and Income Term Fund (NYSE: JPI) and Nuveen Preferred Income Opportunities Fund (NYSE: JPC). The elimination of the funds' existing 40 percent limit on non-U.S. securities reflects the evolution of the preferred securities market over time.
JPI: 24.40 (+0.11), JPC: 10.37 (-0.01)

Four Nuveen Closed-End Funds Declare Capital Gains and Supplemental Income Dividends
BusinessWire - Tue Dec 15, 4:32PM CST
Nuveen Investments, a leading global provider of investment services to institutions, as well as individual investors, today announced that four closed-end funds have declared additional cash distributions with the record, ex-dividend and payable dates outlined below.
JPI: 24.40 (+0.11), JHP: 8.79 (+0.04), JRO: 10.63 (+0.11), JSD: 15.98 (+0.02)

Nuveen Closed-End Funds Declare Monthly Distributions
BusinessWire - Mon Feb 02, 4:00PM CST
Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that 77 Nuveen closed-end funds declared regular monthly distributions and two closed-end funds declared regular quarterly distributions. These funds represent a broad range of tax-exempt, taxable fixed and floating rate income investment strategies for investors seeking to build sophisticated and diversified long-term investment portfolios for cash flow. The funds' monthly distributions are listed below.
NTC: 14.28 (-0.03), NKG: 14.55 (-0.01), NBD: 22.98 (+0.02), NOM: 16.72 (-0.53), JLS: 23.66 (+0.05), JQC: 8.36 (+0.02), NXC: 16.67 (-0.08), JPI: 24.40 (+0.11), JTP: 8.41 (+0.04), JHP: 8.79 (+0.04), NKX: 17.23 (+0.08), NBB: 22.65 (+0.04), NSL: 6.24 (+0.05), JPS: 9.58 (+0.03), NAZ: 17.08 (+0.12), JPW: 16.56 (-0.08), NNC: 14.95 (+0.03), NVX: 16.82 (+0.08), JMT: 23.10 (+0.20), JMM: 7.39 (-0.02), NJV: 16.46 (-0.06), NCB: 18.45 (-0.03), NNP: 14.01 (-0.06), NCA: 11.29 (-0.02), NRK: 14.52 (+0.05), NNY: 10.50 (+0.06), NMI: 12.59 (-0.02), NVG: 16.38 (+0.05), NQI: 14.26 (-0.03), JSD: 15.98 (+0.02), NZF: 15.98 (+0.03), NQM: 16.50 (+0.03), NUW: 19.00 (+0.04), NMA: 14.54 (-0.01), NQP: 15.35 (+0.01), NZH: 15.91 (+0.07), NQS: 15.61 (-0.02), JRI: 17.10 (-0.03), JFR: 10.65 (+0.02), NMY: 14.38 (+0.06), NQU: 14.89 (-0.04), NUO: 16.78 (+0.07), NMZ: 15.00 (+0.04), JRO: 10.63 (+0.11), NUV: 10.72 (+0.03), NMO: 15.07 (+0.01), NYV: 16.19 (-0.06), NMS: 17.10 (unch), NMT: 15.64 (+0.11), NUM: 15.36 (-0.03), NEV: 17.09 (-0.01), NIQ: 13.87 (+0.03), NIO: 14.67 (-0.04), NIM: 10.97 (+0.01), NPI: 15.46 (+0.02), NPF: 15.14 (+0.05), DRA: 17.12 (+0.03), NPM: 15.38 (+0.03), JPC: 10.37 (-0.01), NTX: 15.77 (-0.02), NPP: 16.48 (+0.09), JGH: 15.05 (-0.12), NPN: 17.15 (unch), NXJ: 15.43 (+0.01), NPT: 13.70 (-0.08), NXK: 13.20 (+0.03), NXN: 14.71 (+0.02), NAD: 15.74 (+0.01), NEA: 15.02 (+0.03), NAC: 16.90 (-0.01), NXP: 15.48 (-0.24), NPV: 14.95 (+0.02), NXQ: 14.84 (+0.09), NXR: 15.60 (+0.04), NAN: 15.58 (+0.02), NID: 14.22 (+0.04)

Nuveen Preferred and Income Term Fund Announces Policy Change
BusinessWire - Fri Jan 16, 8:00AM CST
Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that the Board of Trustees of the Nuveen Preferred and Income Term Fund (NYSE: JPI) has approved a change to the fund's investment policies.
JPI: 24.40 (+0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles